Arecor Therapeutics
plc
("Arecor"
or the "Company")
BOARD
CHANGE
ARECOR ANNOUNCES SUSAN
LOWTHER TO STEP DOWN AS CHIEF FINANCIAL OFFICER
Cambridge, UK,
23 April 2024: Arecor Therapeutics plc (AIM:
AREC), the biopharmaceutical group advancing today's therapies to
enable healthier lives, today announced that Susan Lowther has
decided to step down from her role as Chief Financial Officer,
Company Secretary and as a Board Director, to pursue new
opportunities.
A search for Susan's successor is underway and
her last day with Arecor is expected to be on the 22 July, to
ensure an effective handover.
Sarah Howell,
Chief Executive Officer of Arecor, said: "On behalf of the Board and all at Arecor, I want to thank
Susan for her contributions over the past five years, in our
transition to a public company and growth as a business. We wish
her every success in her future plans."
Susan Lowther,
Chief Financial Officer of Arecor, said: "I am proud to have been Arecor's first Chief Financial
Officer and of our achievements as a business, and believe the
Company is well placed for further growth. I will watch the future
progress with interest."
-ENDS-
For more
information, please contact:
|
Arecor
Therapeutics plc
|
www.arecor.com
|
|
Dr Sarah Howell, Chief Executive
Officer
|
Tel: +44 (0) 1223 426060
Email: info@arecor.com
|
|
|
|
|
Susan Lowther, Chief Financial
Officer
|
Tel: +44 (0) 1223 426060
Email: info@arecor.com
|
|
|
|
|
Panmure Gordon
(UK) Limited (NOMAD and Broker)
|
|
|
Freddy Crossley, Emma Earl (Corporate
Finance)
Rupert Dearden (Corporate Broking)
|
Tel: +44 (0) 20 7886 2500
|
|
|
|
|
WG Partners
LLP (Financial Advisor)
|
|
|
Nigel Barnes, Satheesh Nadarajah
David Wilson, Claes Spang
|
Tel: +44 (0)203 705 9321
|
|
|
|
|
ICR
Consilium
|
|
|
Chris Gardner, David Daley, Lindsey
Neville
|
Tel: +44 (0) 20 3709 5700
Email:
arecor@consilium-comms.com
|
|
|
|
Notes to
Editors
About
Arecor
Arecor Therapeutics plc is a globally focused
biopharmaceutical company transforming patient care by bringing
innovative medicines to market through the enhancement of existing
therapeutic products. By applying our innovative proprietary
technology platform, Arestat™, we are developing an internal
portfolio of proprietary products in diabetes and other
indications, as well as working with leading pharmaceutical and
biotechnology companies to deliver therapeutic products. The
Arestat™ platform is supported by an extensive patent
portfolio.
For further details please see our
website, www.arecor.com
